Global Drug-Device Combination Market is Growing with a CAGR of 10.2% in the Forecast Period of 2021 to 2028

The Global Drug-Device Combination Market is growing with factors such as the rising prevalence of chronic diseases and the growing geriatric population. Enabling home treatment and emphasizing technological advancements in healthcare and healthcare combination products also acts as a major factor for the growth of the market. Favorable government initiatives and growing support by healthcare organizations and government bodies have also given a boom to the global drug-device combination market.

Technological advancements have propelled the demand of the market. However, the risk associated with combination products and product recalls has decreased the demand of the market.

Global Drug-Device Combination Market Scenario                    

According to Data Bridge Market Research, the market for global drug-device combinations in North America has the highest market share, followed by Europe and Asia-Pacific. The market leader is Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), which accounts for an estimated market share of approximately 24.45% in the global market. The company has gained outstanding sales by providing novel drug-device combination products.

  • In October 2009, Simponi (Golimumab) received European Approval as a once-monthly subcutaneous anti-TNF for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis with novel Smartject auto-injector. This has strengthened the company’s footprint in Europe and boosted market growth

Drug-Device Combination Market Trends Impacting the Market

Now the question is which other regions Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Amgen Inc. and GlaxoSmithKline Plc. are targeting? Data Bridge Market Research has forecasted a large growth in North America drug-device combination market and the market leaders targeting U.S. and Canada to be their next pocket revenue for 2021.

The drug-device combination market is becoming more competitive with companies like Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Amgen Inc., and GlaxoSmithKline Plc. These are the top dominating companies in the drug-device combination market and have launched novel products, services, and consumables in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global drug-device combination market.

For more analysis on the global drug-device combination market, request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-drug-device-combination-market

Drug-Device Combination Market Developments

  • In January 2020, Amgen Inc. announced successful strategic collaboration with BeiGene. It is predicted that this collaboration enhanced the company’s footprints in the China oncology market in the coming years
  • In October 2020, Glaxosmithkline Plc announced that the European Medicines Agency (EMA) has accepted regulatory submissions seeking approval for the use of anti-IL5 biologic Nucala (mepolizumab) in three additional conditions: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). This has increased the company’s revenue, thereby attracted more customers towards their company
  • In September 2018, Amgen Inc. received marketing approval from the Japanese Ministry of Health, Labour, and Welfare for Blincyto (blinatumomab). The first line usage of Blincyto (blinatumomab) is to treat relapsed or refractory B-cell acute lymphoblastic leukemia. This approval has accelerated the company position in the Japanese market

Scope of the Drug-Device Combination Market

The global drug-device combination market is segmented on the basis of countries into the U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa.

All country-based analysis of the global drug-device combination market is further analyzed based on maximum granularity into further segmentation. On the basis of product, the drug-device combination market is segmented into auto-injector, microneedle patch, digital pill, smart inhaler, drug delivery hydrogels, drug-eluting lens, and others. On the basis of applications, the global drug-device combination market is segmented into orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, and others. On the basis of end-users, the global drug-device combination market is segmented into clinics, hospitals, home care settings, ambulatory care centers, and others. On the basis of distribution channels, the global drug-device combination market is segmented into direct tender, retail sales, and others.

To know more about the study https://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

Key Pointers Covered in Drug-Device Combination Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and overview of drug-device combination market
  • Company profiling of top eight players of drug-device combination market

Key Market Competitors Covered in the Report

  • Medtronic
  • Zimmer Biomet
  •  Amgen Inc.
  • Mediprint
  •  Propeller Health
  •  BD
  • YPSOMED
  •  CosMED Pharmaceutical Co.Ltd.
  •  Micron Biomedical, Inc.
  •  Findair Sp. z o. o.
  • VAXXAS
  • MetP Pharma AG
  •  SONCEBOZ
  •  Eitan Medical
  •  Vaxess Technologies Inc.
  •  Subcuject Aps
  •  E3D Elcam Drug Delivery Devices
  •  OcuMedic
  •  GlaxoSmithKline plc
  •  Bayer AG
  •  NanoPass
  •  Sensirion AG Switzerland
  •  Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson Sevices, Inc.)
  •  Insulet Corporation
  •  TheraJect
  •  Otsuka America Pharmaceutical, Inc.
  •  Raphas Co., Ltd.
  •  EOFLOW CO., LTD.
  •  CGbio

Above are the key players covered in the report. To know about more an exhaustive list of drug-device combination companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-drug-device-combination-market

Research Methodology: Global Drug-Device Combination Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry.

The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market timeline analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis, and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturer, Geneticists, Healthcare Industry, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers, among others.

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/